Drug Profile
Volasertib - Boehringer Ingelheim/Oncoheroes Biosciences
Alternative Names: BI-6727Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Oncoheroes Biosciences
- Class Amides; Antineoplastics; Piperazines; Pteridines; Small molecules
- Mechanism of Action Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia
- Phase II Myelodysplastic syndromes; Non-small cell lung cancer; Ovarian cancer
- No development reported Chronic myelomonocytic leukaemia; Rhabdomyosarcoma; Solid tumours; Urogenital cancer
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for phase-I development in Rhabdomyosarcoma in Unknown (IV, Infusion)
- 05 Mar 2024 Notable Labs plans a phase II trial for Acute myeloid leukemia (Second-line therapy or greater) in the second quarter of 2024
- 23 Feb 2024 Notable Labs plans to file an IND application for Acute myeloid leukemia (Second-line therapy or greater) in Q1 of 2024